课题基金 / 基金详情

Novel Therapeutic Vaccines for Chronic HBV

Novel Therapeutic Vaccines for Chronic HBV
慢性乙型肝炎的新型治疗疫苗
批准号:
8394626
负责人:
Robert G. Whalen
金额:
$30.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-26 至 2014-08-31

项目摘要

项目成果

Robert G. Whalen的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请方提供):B肝炎病毒(HBV)是一种非细胞病变的嗜肝DNA病毒,可导致大多数健康个体发生自限性急性感染,但也可导致慢性感染,特别是在通过垂直传播感染的新生儿中。慢性乙型肝炎B感染是一个重大的全球健康问题,直接影响全球3.5亿人,每年导致50 - 120万人死亡。在围产期获得慢性HBV感染的成人发展为肝细胞癌的比率约为每十年5%,比未感染个体的比率高约100倍。抗病毒药物可以抑制病毒复制,并有助于降低发病率, 死亡率,但它们并不代表治愈。对慢性感染HBV的黑猩猩进行的概念验证研究表明,编码HBV表面抗原(HBsAg)的DNA疫苗,随后进行重组金丝雀痘疫苗接种,可以使HBV DNA水平大幅下降数年。尽管在唯一的非人类模型中取得了令人鼓舞的结果,但治疗性疫苗的临床试验尚未提供足够强的反应来抑制病毒复制。我们假设,混合物的变体HBsAg蛋白含有异种嗜肝DNA病毒的T表位将总理辅助T细胞和CTL识别病毒蛋白在慢性感染的个人,否则响应较差的病毒蛋白。嵌合序列的混合物的使用是创新的;通过组合几种独特的变体,可以覆盖大多数或所有野生型表位,同时最大化免疫刺激序列的含量。这一假设是新颖的,并得到了我们初步研究中获得的数据的间接支持。然而,它显然需要更广泛的实验支持,特别是关于T细胞反应的直接数据,这将由第一阶段SBIR的可行性研究提供。我们建议开发一种治疗性DNA疫苗产品,通过电穿孔和表达HBsAg变体的混合物。已经使用定向分子进化方法鉴定了许多含有具有新型T表位的异种序列的免疫原性HBsAg变体。混合几种变体将通过包括许多不同的异种表位来增加组合疫苗的免疫潜力。从7种个体变体开始,将使用分层策略筛选所有可能的3种变体组合,以鉴定正常和HBsAg转基因小鼠中最具免疫原性的混合物。本提案的主要目的是确定能够诱导强烈T细胞反应且安全且耐受性良好的混合物。这项工作的一个重要特点是在开发的所有阶段都存在潜在的后备候选人。在铅优化的早期阶段推进多个候选人增加了成功结果的可能性.成功开发这种创新的基于DNA的慢性HBV感染治疗性疫苗将填补这种疾病治疗中相当大的未满足需求,这是一个重大的公共卫生负担。 公共卫生相关性:B型肝炎病毒感染可导致某些人患慢性疾病,尤其是新生儿。这是一个主要的健康问题,影响全球超过3.5亿人,每年导致50 - 120万人死亡,通常死于肝癌。我们将研制一种疫苗来治疗这种慢性感染,并有可能治愈这种疾病。
英文摘要
DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a noncytopathic, hepatotropic DNA virus that results in a self-limited acute infection in a majority of otherwise healthy individuals but can also cause chronic infection, particularly in newborns infected by vertical transmission. Chronic hepatitis B infection is a significant global health issue directly affecting 350 million people worldwide and resulting in 0.5-1.2 million deaths per year. Adults with chronic HBV infection acquired in the perinatal period develop hepatocellular carcinoma at a rate of about 5% per decade, approximately 100-fold higher than the rate among uninfected individuals. Antiviral drugs can inhibit viral replication and contribute to reducing morbidity and mortality, but they do not represent a cure. Proof-of-concept studies with chimpanzees chronically infected with HBV have shown that a DNA vaccine encoding the HBV surface antigen (HBsAg) followed by a recombinant canarypox boost can produce a large decline in HBV DNA levels for several years. Despite this encouraging result in the only non-human model, clinical trials of therapeutic vaccines have not provided a strong enough response to suppress viral replication. We hypothesize that mixtures of variant HBsAg proteins containing xenogeneic hepadnavirus T epitopes will prime helper T cells and CTLs to recognize the viral protein in chronically infected individuals, which otherwise respond poorly to the viral protein. The use of mixtures of chimeric sequences is innovative; by combining several unique variants it is possible to cover most or all wild-type epitopes while maximizing the content of immunostimulatory sequences. This hypothesis is novel and indirectly supported by data obtained in our Preliminary Studies. However, it clearly requires more extensive experimental support, notably direct data on T-cell responses, and this will be provided by the feasibility stud of this Phase I SBIR. We propose to develop a therapeutic DNA vaccine product delivered by electroporation and expressing a mixture of HBsAg variants. A number of immunogenic HBsAg variants containing xenogeneic sequences with novel T epitopes have been identified using a directed molecular evolution approach. Mixing several variants will increase the immunotherapeutic potential of the combined vaccine by including many different xenogeneic epitopes. Beginning with seven individual variants, all possible 3-variant combinations will be screened using a tiered strategy to identify the most immunogenic mixtures in normal and HBsAg-transgenic mice. The main objective of this Proposal is to identify mixtures that can induce strong T-cell responses and that are safe and well tolerated. An important feature of this work is the existence of potential backup candidates at all stages of development. Advancing multiple candidates at the early stages of lead optimization increases the likelihood of a successful outcome. Success in developing this innovative DNA-based therapeutic vaccine for chronic HBV infection would fill a considerable unmet need in the treatment of this disease, which represents a major public health burden. PUBLIC HEALTH RELEVANCE: Hepatitis B virus infection can cause chronic disease in certain people, particularly newborns. This is a major health issue affecting over 350 million individuals worldwide resulting in 0.5-1.2 million deaths per year, often from liver cancer. We wil develop a vaccine to treat this chronic infection and potentially cure the disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Tetravalent Vaccines for Dengue Virus
  • 批准号:
    8315393
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
  • 批准号:
    8329484
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
  • 批准号:
    8410439
  • 项目类别:
  • 资助金额:
    $59.78万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
  • 批准号:
    8501370
  • 项目类别:
  • 资助金额:
    $55.15万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
海外基金